Wall Street analysts expect Immatics (NASDAQ:IMTX – Get Rating) to report earnings of $1.86 per share for the current quarter, Zacks reports. Two analysts have issued estimates for Immatics’ earnings, with the highest EPS estimate coming in at $2.07 and the lowest estimate coming in at $1.65. Immatics posted earnings of ($0.41) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 553.7%. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Immatics will report full-year earnings of ($0.21) per share for the current fiscal year, with EPS estimates ranging from ($1.91) to $0.72. For the next fiscal year, analysts anticipate that the business will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.32) to ($1.54). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Immatics.
Immatics (NASDAQ:IMTX – Get Rating) last issued its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of $1.94 by ($2.24). Immatics had a negative return on equity of 154.19% and a negative net margin of 260.05%. The company had revenue of $17.99 million during the quarter, compared to analysts’ expectations of $84.78 million.
IMTX traded up $0.56 on Friday, hitting $6.88. The company had a trading volume of 133,140 shares, compared to its average volume of 116,184. Immatics has a 52-week low of $5.75 and a 52-week high of $16.30. The stock has a fifty day simple moving average of $7.82 and a 200-day simple moving average of $9.87. The firm has a market capitalization of $432.82 million, a P/E ratio of -4.10 and a beta of 0.38.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Immatics during the fourth quarter valued at approximately $41,000. UBS Group AG increased its stake in shares of Immatics by 69.6% during the third quarter. UBS Group AG now owns 3,100 shares of the company’s stock valued at $40,000 after purchasing an additional 1,272 shares in the last quarter. BlackRock Inc. bought a new position in shares of Immatics during the first quarter valued at approximately $27,000. Copernicus Capital Management LLC bought a new position in shares of Immatics during the third quarter valued at approximately $130,000. Finally, MYDA Advisors LLC bought a new position in shares of Immatics during the third quarter valued at approximately $130,000. 36.61% of the stock is owned by institutional investors and hedge funds.
About Immatics (Get Rating)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
- Get a free copy of the StockNews.com research report on Immatics (IMTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.